Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Blood - 24 Sept 2015

Deininger Michael, Radich Jerald, Burn Timothy C, Huber Reid, Paranagama Dilan, Verstovsek Srdan

Abstract excerpt

The JAK2 c.1849G>T (p.V617F) mutation leads to constitutive activation of Janus kinase (JAK)2 and contributes to dysregulated JAK signaling in myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment-I trial, patients with MF, post-PV MF, or post-ET MF achieved significant reductions in splenomegaly and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Nitriles
Share to Point Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Share to Spleen

Share to Splenomegaly

Source

Open in PubMed Open full text

Identifiers

PMID: 26228487
DOI: 10.1182/blood-2015-03-635235
PMCID: PMC4582331

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.PMID 26228487Read ↗

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.Semantic proximity Read ↗

High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Semantic proximity Read ↗

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

JAK2V617F allele burden is associated with transformation to myelofibrosis.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.